Studies on Plasmalogen-Selective Phospholipase A2 in Brain

被引:0
|
作者
Akhlaq A. Farooqui
机构
[1] The Ohio State University,Department of Molecular and Cellular Biochemistry
来源
Molecular Neurobiology | 2010年 / 41卷
关键词
Phospholipase A; Alzheimer disease; Plasmalogen; Eicosanoids; Docosanoids; Ceramide; Kainic acid toxicity;
D O I
暂无
中图分类号
学科分类号
摘要
Plasmalogen-selective phospholipase A2 (PlsEtn-PLA2) has been purified from pig brain using multiple column chromatographic procedure. The purified enzyme migrates as a single band on polyacrylamide. It is stimulated by Triton X-100 and inhibited by sodium deoxycholate. Purified PlsEtn-PLA2 is inhibited by iodoacetate, and this inhibition can be prevented by β-meracaptoethanol. Treatment of neuronal cell cultures with kainic acid stimulates PlsEtn-PLA2 activity in a dose-dependent manner, and this stimulation can be blocked by Ly294486, a selective kainic acid receptor antagonist. Activities of PlsEtn-PLA2 are markedly increased in plasma membrane and synaptosomal plasma membrane fraction prepared from nucleus basalis and hippocampal region of brains from Alzheimer disease patients compared to age-matched controls. It is proposed that accumulation of ceramide and increased expression of cytokines may be responsible for the stimulation of PlsEtn-PLA2 in Alzheimer disease.
引用
收藏
页码:267 / 273
页数:6
相关论文
共 50 条
  • [41] Phospholipase A2 activity is associated with structural brain changes in schizophrenia
    Smesny, Stefan
    Milleit, Berko
    Nenadic, Igor
    Preul, Christoph
    Kinder, Daniel
    Lasch, Juergen
    Willhardt, Ingo
    Sauer, Heinrich
    Gaser, Christian
    NEUROIMAGE, 2010, 52 (04) : 1314 - 1327
  • [42] Chronic Lithium Treatment Decreases Brain Phospholipase A2 Activity
    Michael C. J. Chang
    Collins R. Jones
    Neurochemical Research, 1998, 23 : 887 - 892
  • [43] Chronic lithium treatment decreases brain phospholipase A2 activity
    Chang, MCJ
    Jones, CR
    NEUROCHEMICAL RESEARCH, 1998, 23 (06) : 887 - 892
  • [44] Secretory phospholipase A2
    Murakami, M
    Kudo, I
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (08) : 1158 - 1164
  • [45] Phospholipase A2 Biochemistry
    Burke, John E.
    Dennis, Edward A.
    CARDIOVASCULAR DRUGS AND THERAPY, 2009, 23 (01) : 49 - 59
  • [46] Phospholipase A2 inhibitors
    Garcia-Garcia, Hector M.
    Serruys, Patrick W.
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (04) : 327 - 332
  • [47] Phospholipase A2 enzymes
    Kudo, I
    Murakami, M
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 : 3 - 58
  • [48] Phospholipase A2 in Cnidaria
    Nevalainen, TJ
    Peuravuori, HJ
    Quinn, RJ
    Llewellyn, LE
    Benzie, JAH
    Fenner, PJ
    Winkel, KD
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2004, 139 (04): : 731 - 735
  • [49] Phospholipase A2 in porifera
    Nevalainen, TJ
    Quinn, RJ
    Hooper, JNA
    COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 2004, 137 (03): : 413 - 420
  • [50] Lysosomal phospholipase A2
    Shayman, James A.
    Tesmer, John J. G.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2019, 1864 (06): : 932 - 940